Mutations of the PIK3CA gene in diffuse large B cell lymphoma

Diagnostic Molecular Pathology

Volumn 17, Issue 3, 2008, Pages 159-165

  Yu, Baohua ^a   Zhou, Xiaoyan ^a   Zhang, Tiecheng ^a   Qin, Tao ^a   Shi, Daren ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

DLBCL; Mutation; pAKT; PIK3CA

Indexed keywords

ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN PIK3CA; UNCLASSIFIED DRUG; PIK3CA PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXON; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; WESTERN BLOTTING; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 54049145155     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31815d0588     Document Type: Article

References (39)

1. Coiffler B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001;13:325-334.
2. Wang L, Fortney JE, Gibson LF. Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active AKT. Leuk Res. 2004;28:733-742.
3. Grewe M, Gansauge F, Schmid RM, et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 1999;59: 3581-3587.
4. Wong YC, Wang YZ. Growth factors and epithelial-stromal interactions in prostate cancer development. Int Rev Cytol. 2000;199:65-116.
5. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/AKT signaling. Oncogene. 2003;22:974-982.
6. Roy HK, Olusola BF, Clemens DL, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis. 2002;23:201-205.
7. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-1657.
8. Nicholson KM, Anderson NG. The protein kinase B/AKT signalling pathway in human malignancy. Cell Signal. 2002;14: 381-395.
9. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2: 489-501.
10. Smith PG, Wang F, Wilkinson KN, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood. 2005;105:308-316.
11. Lu X, Nechushtan H, Ding F, et al. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood. 2005;105:2924-2932.
12. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006;108:4178-4186.
13. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001;61:7426-7429.
14. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21:99-102.
15. Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene. 2000;19:2739-2744.
16. Hui AB, Lo KW, Yin XL, et al. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest. 2001;81:717-723.
17. Wu G, Mambo E, Guo Z, et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 2005;90:4688-4693.
18. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304:554.
19. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64: 7678-7681.
20. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561-573.
21. Bousquet M, Recher C, Queleen C, et al. Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia. Br J Haematol. 2005;131: 411-113.
22. David O, Jett J, LeBeau H, et al. Phospho-Akt Overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res. 2004;10: 6865-6871.
23. Stal O, Perez-Tenorio G, Akerberg L, et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 2003;5:R37-R44.
24. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of AKT contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006;108:1668-1676.
25. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol. 2004;15:171-176.
26. Hill MM, Hemmings BA. Inhibition of protein kinase B/AKT implications for cancer therapy. Pharmacol Ther. 2002;93: 243-251.
27. Gao N, Nester RA, Sarkar MA. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/AKT/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol Appl Pharmacol. 2004;196:124-135.
28. Gao N, Zhang Z, Jiang BH, et al. Role of P13K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun. 2003;310:1124-1132.
29. Knobbe CB, Trampe-Kieslich A, Reifenberger G. Genetic alteration and expression of the phosphoinositol-3-kinase/AKT pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol. 2005;31:486-490.
30. Kurose K, Zhou XP, Araki T, et al. Frequent loss of PTEN expression is linked to elevated phosphorylated AKT levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol. 2001;158:2097-2106.
31. Pandolfi PP. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med. 2004;351:2337-2338.
32. Nakahara Y, Nagai H, Kinoshita T, et al. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia. 1998;12:1277-1280.
33. Sakai A, Thieblemont C, Wellmann A, et al. PTEN gene alterations in lymphoid neoplasms. Blood. 1998;92:3410-3415.
34. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA. 2005;102:802-807.
35. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005;24:1477-1480.
36. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005;65:4562-4567.
37. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005; 11:2875-2878.
38. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. PNAS. 2005; 102:802-807.
39. Hummerdal P, Andersson P, Willander K, et al. Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia. Eur J Haematol. 2006;77:86-87.